Aoife Brennan
CIK 1714563 · President and CEO · last filed 2026-01-08
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$176.8K
Companies
5
Total Filings
25
Lifetime Open-Market Net
-$139.2K
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| Climb Bio, Inc. (ELYM) Delisted | President and CEO | 48,132 | $5.11 | $246.0K | -$25.2K | 4 | 2026-01-08 |
| XLO | Director | — | $8.31 | — | $0 | 2 | 2025-06-12 |
| KYNTRA BIO, INC. (FGEN) Delisted | Director | 27,947 | $9.75 | $272.5K | -$81.4K | 5 | 2024-06-06 |
| SYBX | President and CEO | 256,301 | $0.69 | $176.8K | -$32.7K | 11 | 2023-11-14 |
| Ra Pharmaceuticals, Inc. (RARX) Delisted | Director | — | — | — | $0 | 3 | 2020-04-03 |
Recent Filings · Page 2 of 3
25 filingsForm 4 transactions across all companies, newest first.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2022-06-21 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | +15,777 | $0 | EDGAR |
| 2022-04-06 | SYBX | Sell (S) | −8,894 | -$21.8K | EDGAR |
| 2022-02-08 | SYBX | Grant (A) | +106,920 | $0 | EDGAR |
| 2021-05-28 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | +4,700 | $0 | EDGAR |
| 2021-03-12 | SYBX | Grant (A) | +71,250 | $0 | EDGAR |
| 2020-08-07 | KYNTRA BIO, INC. (FGEN) Delisted | Grant (A) | +3,914 | $0 | EDGAR |
| 2020-04-03 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Disp (D) | — | $0 | EDGAR |
| 2020-03-12 | SYBX | Grant (A) | +46,300 | $0 | EDGAR |
| 2019-09-25 | SYBX | Grant (A) | +8,000 | $0 | EDGAR |
| 2019-06-13 | Ra Pharmaceuticals, Inc. (RARX) Delisted | Grant (A) | — | $0 | EDGAR |
Codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.